Related Experiment Video

Updated: Aug 6, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Synergistic antimyeloma effects of zoledronate and simvastatin

Ralf Schmidmaier1, Meral Simsek, Philipp Baumann

  • 1Department of Medicine Innenstadt, Division of Hematology and Oncology, University Hospital Munich, Munich, Germany. ralf.schmidmaier@med.uni-muenchen.de

Anti-Cancer Drugs
|August 19, 2006
PubMed

Insights

Simvastatin effectively induces apoptosis in multiple myeloma cells, overcoming drug resistance. Combining zoledronate and simvastatin synergistically enhances this effect and reverses resistance, suggesting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Multiple myeloma remains incurable due to drug resistance.
  • Mevalonate pathway inhibitors (bisphosphonates, statins) show in vitro antimyeloma activity at high concentrations.
  • Achieving effective in vivo concentrations of these inhibitors is challenging.

Purpose of the Study:

  • To investigate the antimyeloma activity of simvastatin and zoledronate, alone and in combination with standard drugs.
  • To evaluate their efficacy in overcoming cell-adhesion-mediated drug resistance.
  • To explore sequential mevalonate pathway inhibition strategies.

Main Methods:

  • Treatment of multiple myeloma cell lines (NCI-H929, OPM-2, U266, RPMI-8226) with simvastatin or zoledronate.
  • Co-culture with bone marrow stromal cells to mimic the in vivo environment.
  • Combination therapy with melphalan or bortezomib.
  • Assessment of apoptosis induction and drug resistance reversal.

Main Results:

  • Simvastatin demonstrated potent apoptosis induction in myeloma cells, independent of cell adhesion.
  • Zoledronate showed limited activity at lower concentrations.
  • Sequential inhibition with zoledronate and simvastatin synergistically induced apoptosis and reversed cell-adhesion-mediated drug resistance.

Conclusions:

  • Simvastatin is a potent inducer of apoptosis in multiple myeloma cells.
  • Sequential blockade of the mevalonate pathway by zoledronate and simvastatin offers a synergistic approach.
  • Combining zoledronate and simvastatin with conventional therapies may overcome drug resistance in multiple myeloma.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...